Theratechnologies Expands Peptide Portfolio in Endocrinology with the Addition of a GLP-1 Program for the Treatment of Type II Diabetes (Canada NewsWire)

Dow Obtains Patents for Production of Glycoproteins In Transgenic Plant Systems (PR Newswire)
..."Meeting these challenges can result in lower production costs, increased half-life of the protein in the body, and i...

Actinium Pharmaceuticals Announces Collaboration with Memorial Sloan Kettering Cancer Center for a Novel Targeted Cancer Immunotherapy (PR Newswire)
..."API brings its supporting patent position for use of these unique, short half-life alpha-particle emitting radioisot...

MGI PHARMA & HELSINN Submit NDA for Palonosetron (Business Wire)
... selective 5-HT3 receptor antagonist with a strong receptor-binding affinity and an extended plasma half-life, in dev...

Theratechnologies Expands Peptide Portfolio in Endocrinology with the Addition of a GLP-1 Program for the Treatment of Type II Diabetes (PR Newswire)
... hydrophobic chain to peptides in order to slow their enzymatic degradation and increase their half-life.......

Enzon Reports Schering-Plough Announces Launch of PEG-INTRON Pre-Filled Pen in Europe (Business Wire)
... once-weekly therapy designed to optimize the balance between antiviral activity and elimination half-life.......

BioSyntech Inc.: A Novel Non-Toxic Sustained Release Taxol Formulation for Cancer Chemotherapy (CCNMatthews)
...It is understandable based on the half life (t1/2) of about 6 hours for the free Taxol.......